REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Furmonertinib Mesilate Tablets Monotherapy
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06962865
- Locations
- 🇨🇳
Beijing Chest Hospital,Capital Medical Unniversity, Beijing, China
🇨🇳The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, China
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric Carcinoma
- Interventions
- Biological: Tislelizumab+Oxaliplatin+CapecitabineBiological: Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 616
- Registration Number
- NCT06944496
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, BJ-Beijing, China
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: RC148 plus Carboplatin and Paclitaxel/pemetrexed
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06883630
- Locations
- 🇨🇳
Shunde Hospital of Southern Medical University, Foshan, Guangdong, China
🇨🇳Beijing Tiantan Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06642545
- Locations
- 🇨🇳
Cance Hosoltal Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT06549959
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Tianjin People's Hospital, Tianjin, Tianjin, China
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Remegen Co. Ltd.
- Target Recruit Count
- 72
- Registration Number
- 2024-512126-29-00
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen Oe, Denmark
🇩🇰Aarhus Universitetshospital, Aarhus N, Denmark
🇮🇹Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli, Naples, Italy
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06456567
- Locations
- 🇺🇸
Hemet site, Hemet, California, United States
🇺🇸Menifee site, Menifee, California, United States
🇺🇸Rockford site, Rockford, Illinois, United States
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06378242
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital,SunYat-sen University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳Hunan Cancer hospital, Changsha, Hunan, China
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Disitamab Vedotin Injection （12 weeks）Drug: Disitamab Vedotin Injection （18 weeks）Drug: Sequential CTX
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06227117
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China